Search

Baxdrostat

It targets aldosterone excess, a primary underlying driver of treatment resistance and organ damage in cardiovascular diseases [A275512, A275515]. … On May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189].

Calcimycin

Primarily used as a biochemical tool for studying divalent cations in biological systems, Calcimycin also exhibits antibiotic activity against gram-positive bacteria and fungi.

Azadirachtin

Azadirachtin is under investigation in clinical trial NCT06617026 (Short-term Outcome of Medical vs. Surgical Management of Chronic Anal Fissure).

Oveporexton

[L64069] Oveporexton has been recommended for scheduling as a controlled substance, and its final controlled-substance schedule and commercial availability are pending a determination by the Drug Enforcement

Dexfadrostat

Dexfadrostat is under investigation in clinical trial NCT04007406 (DP13 - a Phase II Study in Patients With Primary Aldosteronism).

Milsaperidone

Milsaperidone is an atypical antipsychotic agent that rapidly interconverts to iloperidone in vivo. Atypical antipsychotic agents work by blocking the D2 dopamine and serotonin receptor signalling pathways. Similarly, milsaperidone acts ...

AS-602868

Talbutal

Talbutal, also called 5-allyl-5-sec-butylbarbituric acid, is a barbiturate with a short to intermediate duration of action. Talbutal is a schedule III drug in the U.S.

Ethoxzolamide

Ethoxzolamide is a sulfonamide used as diuretic and in glaucoma. It inhibits carbonic anhydrase activity in proximal renal tubules to decrease reabsorption of water, sodium, potassium, bicarbonate.

Amitriptyline

Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961.